Fisher Asset Management LLC Lowers Stake in Prestige Consumer Healthcare Inc. $PBH

Fisher Asset Management LLC lowered its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 6.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 273,885 shares of the company’s stock after selling 19,824 shares during the period. Fisher Asset Management LLC’s holdings in Prestige Consumer Healthcare were worth $16,896,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its position in shares of Prestige Consumer Healthcare by 10.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after buying an additional 60,496 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Prestige Consumer Healthcare by 547.4% during the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after buying an additional 520,186 shares in the last quarter. Leeward Investments LLC MA raised its position in shares of Prestige Consumer Healthcare by 23.3% during the 4th quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock valued at $23,894,000 after buying an additional 73,162 shares in the last quarter. JPMorgan Chase & Co. raised its position in Prestige Consumer Healthcare by 30.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock worth $28,656,000 after purchasing an additional 106,224 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in Prestige Consumer Healthcare by 1.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after purchasing an additional 21,085 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on PBH. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Jefferies Financial Group decreased their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $48.23 on Thursday. The firm’s 50-day moving average price is $55.16 and its two-hundred day moving average price is $60.64. Prestige Consumer Healthcare Inc. has a 12-month low of $42.62 and a 12-month high of $87.12. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of 12.34, a PEG ratio of 1.54 and a beta of 0.40. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. During the same quarter in the previous year, the firm posted $1.32 EPS. Prestige Consumer Healthcare’s revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Insider Activity

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).